1 domain / 2 areas / 1 specialization
Blackhawk Growth Corp
Data updated
Blackhawk Growth Corp. is a publicly traded Canadian investment holding company / investment issuer that invests in equity and debt instruments of companies to generate shareholder returns. Public filings and exchange listings place the company in Vancouver, British Columbia, Canada, while the company itself has also described its strategy as active support for portfolio companies in North America.
It matters in the psychedelic ecosystem because Blackhawk has publicly backed psychedelic-related drug development, including MindBio Therapeutics, which it described as a clinical-stage company pioneering psychedelic microdosing research. That makes Blackhawk a relevant crossover investor in the adjacent cannabis, mental health, and psychedelic therapeutics landscape rather than a pure-play life sciences fund.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Public Portfolio Examples
- MindBio Therapeuticsprivate investment - Aug 31, 2021
Blackhawk Growth Corp. appears to operate as a public investment holding company with a broad high-growth mandate, using equity and debt investments and, in some cases, active involvement with portfolio companies. Its public materials emphasize North American deal activity, and its psychedelic relevance comes mainly through exposure to psychedelic drug-development companies such as MindBio Therapeutics, which it has described in connection with microdosing research and emerging therapies.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Recorded Investments
Aug 31, 2021
private investment
Publicly described by Blackhawk as an investment in a psychedelic microdosing and drug-development company.
BLACKHAWK GROWTH TO COMPLETE INVESTMENT IN PSYCHEDELIC ANDQuick Facts
- Founded
- 1986
- HQ
- Suite 2200, 885 West Georgia Street, Vancouver, British Columbia, Canada
- Website
- Visit